Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: An area under the curve analysis Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Vender, Ronald
  • Leonardi, Craig
  • Puig, Luis
  • Ziv, Michael
  • Zhao, Yang
  • Gilloteau, Isabelle
  • McLeod, Lori
  • Nyirady, Judit
  • Guana, Adriana

publication date

  • June 1, 2017